Florian Jehle, Vifor Fresenius Medical Care Renal Pharma CEO
Not so fast, Teva. Vifor wins a few more years of protection from a potential Velphoro generic
Weeks after snapping up the chronic kidney disease drug Velphoro in its $11.7 billion Vifor buyout, CSL pulled in a court win that gives it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
